docetaxel anhydrous has been researched along with ginsenoside rh2 in 2 studies
| Studies (docetaxel anhydrous) | Trials (docetaxel anhydrous) | Recent Studies (post-2010) (docetaxel anhydrous) | Studies (ginsenoside rh2) | Trials (ginsenoside rh2) | Recent Studies (post-2010) (ginsenoside rh2) |
|---|---|---|---|---|---|
| 12,110 | 3,216 | 6,920 | 295 | 1 | 200 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Adomat, H; Bally, MB; Eberding, A; Fazli, L; Guns, ET; Hurtado-Coll, A; Jia, W; Musende, AG; Wood, C | 1 |
| Bally, MB; Eberding, A; Guns, ET; Jia, W; Musende, AG; Ramsay, E | 1 |
2 other study(ies) available for docetaxel anhydrous and ginsenoside rh2
| Article | Year |
|---|---|
Pre-clinical evaluation of Rh2 in PC-3 human xenograft model for prostate cancer in vivo: formulation, pharmacokinetics, biodistribution and efficacy.
Topics: Administration, Oral; Alanine Transaminase; Animal Structures; Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Aspartate Aminotransferases; Body Weight; Cell Line, Tumor; Creatinine; Docetaxel; Drug Stability; Ginsenosides; Humans; Ki-67 Antigen; Male; Mice; Mice, Nude; Prostatic Neoplasms; Solubility; Solvents; Taxoids; Tissue Distribution; Treatment Outcome; Xenograft Model Antitumor Assays | 2009 |
Rh2 or its aglycone aPPD in combination with docetaxel for treatment of prostate cancer.
Topics: Analysis of Variance; Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Docetaxel; Dose-Response Relationship, Drug; Drug Therapy, Combination; Drugs, Chinese Herbal; Ginsenosides; Humans; Male; Mice; Mice, Nude; Prostatic Neoplasms; Taxoids | 2010 |